规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
靶点 |
Vitamin D receptor
|
---|---|
体外研究 (In Vitro) |
在接受肾切除术的小鼠中,多克骨化醇(100 或 300 皮克/克体重)可将血清钙和甲状旁腺激素 (PTH) 水平恢复至正常。在接受肾切除术的小鼠中,多克骨化醇(300 pg/g bw)可显着降低纤维性骨炎。在给予高盐 (HS) 饮食的大鼠中,多克骨化醇显着减少心脏肥大并增强心脏功能。在喂食高盐 (HS) 饮食的大鼠中,多克骨化醇治疗导致组织心房钠尿因子 (ANF) mRNA 水平和血浆脑钠尿肽 (BNP) 水平显着降低。此外,多克骨化醇可显着降低蛋白激酶 C-α (PKCα) 水平,表明维生素 D 缺乏与 PKC 介导的心脏肥大之间可能存在联系。在饮食诱导的肥胖 (DIO) 小鼠中,多克骨化醇可减少蛋白尿、足细胞损伤、系膜生长和细胞外基质蛋白积累。在 DIO 小鼠中,doxercalciferol 还可以减少促纤维化生长因子、促炎细胞因子、氧化应激和巨噬细胞浸润。此外,doxercalciferol 抑制 DIO 小鼠的肾素-血管紧张素-醛固酮系统激活,其中包括血管紧张素 II 1 型受体和盐皮质激素受体。在小鼠中,多克骨化醇和氯沙坦的组合最有效地预防白蛋白尿,恢复肾小球滤过屏障的结构,并以剂量依赖性方式显着降低肾小球硬化。当多克骨化醇和氯沙坦联合使用时,小鼠的糖尿病肾脏几乎没有表现出形态或分子变化。
|
体内研究 (In Vivo) |
在 5/6 肾切除 (NX) 大鼠中,第 6 周时,多克骨化醇(0.083、0.167 或 0.333 μg/kg,腹腔注射)可升高血清磷。此外,多克骨化醇(0.167 和 0.333 μg/kg)可增强脉搏波速度 (PWV) 的增加)在第 6 周的 5/6 肾切除 (NX) 大鼠中,并在第 2 周和第 6 周升高血清钙和 Ca × P。多克骨化醇将血清 PTH 降低至 SHAM 水平,并防止 PTH 上升至 0.083 μg/kg[1]。在饲喂高脂肪饮食的 NON 小鼠中,多克骨化醇(125 ng/kg,腹腔注射,每周 3 次)增加 VDR mRNA 水平的表达和 TRPV5 的肾表达。在接受 HF 饮食的小鼠中,多克骨化醇还可以减少蛋白尿,阻止足细胞损失,并减少细胞外基质蛋白的积累。在饲喂 HF 饮食的小鼠中,多克骨化醇可阻断肾素-血管紧张素-醛固酮系统表达的增加,并抑制促纤维化生长因子(TGF-β、PAI-1 和结缔组织生长因子 (CTGF))的表达。此外,Doxercalciferol 还可抑制巨噬细胞的浸润,降低 NF-κb 活性,停止促炎细胞因子的表达,并阻止高脂饮食小鼠肾脂质的积累[2]。当对链脲佐菌素诱导的糖尿病小鼠每周 3 次腹膜内 (ip) 给药时,多克骨化醇 (30 ng/kg) 显着减轻足细胞损失和细胞凋亡,并减少肾小球纤维化[3]。
|
动物实验 |
Rats: One week following nephrectomy, male Sprague-Dawley 5/6 nephrectomized (NX) rats (∼200 mg) are used. A typical surgical ablation procedure consisting of two steps is used to perform the nephrectomy. Rats are kept on a high-phosphorus diet (0.9% phosphorus and 0.6% calcium) for the duration of the study starting two weeks after nephrectomy in order to cause secondary hyperparathyroidism. Day 0: Vehicle (5% EtOH/95% propylene glycol; 0.4 mL/kg; i.p.) or VDRA (paricalcitol or Doxercalciferol; 0.083, 0.167, or 0.333 μg/kg; intraperitoneally) is given three times a week for 41 days (n = 6–10 per group) to SHAM and 5/6 NX rats (n = 7–10 per group). These dosages were selected because, in this CKD model, after two or six weeks of treatment, lower doses (0.021 and 0.042 μg/kg; i.p.) of either compound do not suppress PTH. Days 0 through 41 are when blood is drawn (24 hours after the dose). Animals are given ketamine (50 mg/kg) anesthesia on Days 0, 13, and 41 (24 h post-dose), and blood is drawn from the tail vein for measurements of PTH and serum blood chemistry[1].
|
参考文献 |
|
分子式 |
C28H44O2
|
|
---|---|---|
分子量 |
412.65
|
|
精确质量 |
412.33
|
|
元素分析 |
C, 81.50; H, 10.75; O, 7.75
|
|
CAS号 |
54573-75-0
|
|
相关CAS号 |
trans-Doxercalciferol;74007-20-8;Impurity of Doxercalciferol;127516-23-8
|
|
外观&性状 |
White to yellow/brown solid powder
|
|
SMILES |
C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C
|
|
InChi Key |
HKXBNHCUPKIYDM-CGMHZMFXSA-N
|
|
InChi Code |
InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1
|
|
化学名 |
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
|
|
别名 |
|
|
HS Tariff Code |
2934.99.9001
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4234 mL | 12.1168 mL | 24.2336 mL | |
5 mM | 0.4847 mL | 2.4234 mL | 4.8467 mL | |
10 mM | 0.2423 mL | 1.2117 mL | 2.4234 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02859896 | Active Recruiting |
Drug: Doxercalciferol (GZ427397) Drug: Calcitriol |
Secondary Hyperparathyroidism- Chronic Kidney Disease |
Sanofi | January 19, 2017 | Phase 3 |
NCT00889629 | Completed | Drug: Doxercalciferol Drug: placebo |
Chronic Kidney Disease Kidney Transplantation |
Mariana Markell | November 2008 | Phase 4 |
NCT00285467 | Completed | Drug: doxercalciferol Drug: Cholecalciferol |
Renal Osteodystrophy | Indiana University School of Medicine |
January 2006 | Not Applicable |
NCT02282813 | Completed | Drug: Doxercalciferol Drug: Calcitriol |
Chronic Kidney Disease Vitamin D Deficiency |
OPKO Health, Inc. | April 2013 | Phase 3 |
NCT00792857 | Completed | Drug: CTAP201 Injection Drug: Doxercalciferol |
Chronic Kidney Disease Chronic Renal Failure |
OPKO IP Holdings II, Inc. | November 2008 | Phase 1 |
Effects of vehicle, paricalcitol or doxercalciferol (0.083, 0.167 and 0.333 μg/kg) i.p. three times per week for 6 weeks on (A) PTH, (B) total calcium, (C) phosphorus and (D) Ca × P levels in 5/6 NX rats fed with a high phosphorus diet (n = 6–10 per group). Nephrol Dial Transplant . 2008 Dec;23(12):3824-30. td> |
Effects of vehicle, paricalcitol or doxercalciferol (0.083, 0.167 and 0.333 μg/kg) i.p. three times per week for 6 weeks on PWV in 5/6 NX rats fed with a high phosphorus diet (n = 6–10 per group). Nephrol Dial Transplant . 2008 Dec;23(12):3824-30. td> |
Treatment of NON mice fed a HF diet with doxercalciferol prevents renal oxidative stress. Am J Physiol Renal Physiol . 2011 Mar;300(3):F801-10. td> |
Treatment of NON mice fed a HF diet with doxercalciferol prevents the increase in renal lipid accumulation. Am J Physiol Renal Physiol . 2011 Mar;300(3):F801-10. td> |
Treatment with doxercalciferol increases farnesoid X receptor (FXR) expression in NON mice fed with HF diet. **P < 0.05 vs. NON mice on HF diet with Veh (n = 6 mice per group). Am J Physiol Renal Physiol . 2011 Mar;300(3):F801-10. td> |